Biopharma venture financing retreats, but not by much
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
Last-ditch rally saves 2019 float tally
A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.
Medtech venture investors wait longer for an exit
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
Bloated on arrival? Biotech's weightiest new issues
A big valuation at float is no guarantee of ongoing investor support, as a look at the sector’s biggest IPOs reveals.
Storm clouds gather for biotech flotations
Only seven drug developers managed to float on Western exchanges in the third quarter, and new issues in October have struggled, with Biontech the latest example.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
The contrasting fortunes of Envista and Smiledirectclub
Two dental companies go public inside a week, with very different results.
A recap on the past few months of data digging and analysis
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
Livongo enters the medtech float hall of fame
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.